Bibliography
- Epstein JB, Gorsky M, Caldwell J. Fluconazole mouth rinses for oral candidiasis in postirradiation, transplant, and other patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002;93(6):671-5
- Finlay PM, Richardson MD, Robertson AG. A comparative study of the efficacy of fluconazole and amphotericin B in the treatment of oropharyngeal candidosis in patients undergoing radiotherapy for head and neck tumours. Br J Oral Maxillofac Surg 1996;34(1):23-5
- Rothan-Tondeur M, Lancien E, Pialleport T, et al. Prevalence of oropharyngeal candidiasis in geriatric inpatients. J Am Geriatr Soc 2001;49(12):1741-2
- Davies AN, Brailsford S, Broadley K, Beighton D. Oral yeast carriage in patients with advanced cancer. Oral Microbiol Immunol 2002;17(2):79-84
- Lerman MA, Laudenbach J, Marty FM, et al. Management of oral infections in cancer patients. Dent Clin North Am 2008;52(1):129-53
- Perlroth J, Choi B, Spellberg B. Nosocomial fungal infections: epidemiology, diagnosis, and treatment. Med Mycol 2007;45(4):321-46
- Ellepola AN, Samaranayake LP. Adjunctive use of chlorhexidine in oral candidoses: a review. Oral Dis 2001;7(1):11-7
- Soysa NS, Samaranayake LP, Ellepola AN. Antimicrobials as a contributory factor in oral candidosis: a brief overview. Oral Dis 2008;14(2):138-43
- Davies AN, Brailsford SR, Beighton D. Oral candidosis in patients with advanced cancer. Oral Oncol 2006;42(7):698-702
- Li XS, Sun JN, Okamoto-Shibayama K, Edgerton M. Candida albicans cell wall ssa proteins bind and facilitate import of salivary histatin 5 required for toxicity. J Biol Chem 2006;281(32):22453-63
- Contucci AM, Inzitari R, Agostino S, et al. Statherin levels in saliva of patients with precancerous and cancerous lesions of the oral cavity: a preliminary report. Oral Dis 2005;11(2):95-9
- Turner MD, Ship JA. Dry mouth and its effects on the oral health of elderly people. J Am Dent Assoc 2007;138(Suppl):15S-20S
- Guggenheimer J, Moore PA. Xerostomia: etiology, recognition and treatment. J Am Dent Assoc 2003;134(1):61-9; quiz 118-9
- Burlage FR, Coppes RP, Meertens H, et al. Parotid and submandibular/sublingual salivary flow during high dose radiotherapy. Radiother Oncol 2001;61(3):271-4
- Shiboski CH, Hodgson TA, Ship JA, Schiodt M. Management of salivary hypofunction during and after radiotherapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007;103(Suppl):S66 e1-19
- Villar CC, Dongari-Bagtzoglou A. Immune defence mechanisms and immunoenhancement strategies in oropharyngeal candidiasis. Expert Rev Mol Med 2008;10:e29
- Vernillo AT. Dental considerations for the treatment of patients with diabetes mellitus. J Am Dent Assoc 2003;134 Spec No:24S-33S
- Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004;38(2):161-89
- Worthington HV, Clarkson JE, Eden OB. Interventions for treating oral candidiasis for patients with cancer receiving treatment. Cochrane Database Syst Rev 2007;(2):CD001972
- Elad S, Wexler A, Garfunkel AA, et al. Oral candidiasis prevention in transplantation patients: a comparative study. Clin Transplant 2006;20(3):318-24
- Ship JA. Diabetes and oral health: an overview. J Am Dent Assoc 2003;134 Spec No:4S-10S
- Yagiela JA, Dowd FJ, Neidle EA. Pharmacology and therapeutics for dentistry. 5th Edition. St. Louis, Missouri: Elsevier Mosby, 2004
- Lodi G, Tarozzi M, Sardella A, et al. Miconazole as adjuvant therapy for oral lichen planus: a double-blind randomized controlled trial. Br J Dermatol 2007;156(6):1336-41
- Vellappally S, Fiala Z, Smejkalova J, et al. Smoking-related systemic and oral diseases. Acta Medica (Hradec Kralove) 2007;50(3):161-6
- Soysa NS, Ellepola AN. The impact of cigarette/tobacco smoking on oral candidosis: an overview. Oral Dis 2005;11(5):268-73
- Kaplan JE, Masur H, Holmes KK. Guidelines for preventing opportunistic infections among HIV-infected persons–2002. Recommendations of the U.S. public health service and the infectious diseases society of America. MMWR Recomm Rep 2002;51(RR-8):1-52
- Dykewicz CA. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis 2001;33(2):139-44
- Wynn R, Meiller T, Crossley H. Drug information handbook for dentistry. 13th edition. Hudson, Ohio: Lexi-Comp, 2007
- Pfizer. DIFLUCAN. Available from: http://www.pfizer.com/pfizer/download/uspi_diflucan.pdf [Cited 2004]
- Corvo R, Amichetti M, Ascarelli A, et al. Effects of fluconazole in the prophylaxis of oropharyngeal candidiasis in patients undergoing radiotherapy for head and neck tumour: results from a double-blind placebo-controlled trial. Eur J Cancer Care (Engl) 2008;17(3):270-7
- Garey KW, Pai MP, Suda KJ, et al. Inadequacy of fluconazole dosing in patients with candidemia based on Infectious Diseases Society of America (IDSA) guidelines. Pharmacoepidemiol Drug Saf 2007;16(8):919-27
- Kishel JJ, Sivik J. Breakthrough invasive fungal infection in an immunocompromised host while on posaconazole prophylaxis: an omission in patient counseling and follow-up. J Oncol Pharm Pract 2008;14(4):189-93
- Nicolatou-Galitis O, Velegraki A, Sotiropoulou-lontou A, et al. Effect of fluconazole antifungal prophylaxis on oral mucositis in head and neck cancer patients receiving radiotherapy. Support Care Cancer 2006;14(1):44-51
- Clarkson JE, Worthington HV, Eden OB. Interventions for preventing oral candidiasis for patients with cancer receiving treatment. Cochrane Database Syst Rev 2007;(1):CD003807
- Epstein JB, Hancock PJ, Nantel S. Oral candidiasis in hematopoietic cell transplantation patients: an outcome-based analysis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003;96(2):154-63
- Soysa NS, Samaranayake LP, Ellepola AN. Cytotoxic drugs, radiotherapy and oral candidiasis. Oral Oncol 2004;40(10):971-8
- Epstein JB, Truelove EL, Hanson-Huggins K, et al. Topical polyene antifungals in hematopoietic cell transplant patients: tolerability and efficacy. Support Care Cancer 2004;12(7):517-25
- Powderly WG, Finkelstein D, Feinberg J, et al. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med 1995;332(11):700-5
- Epstein JB, Ransier A, Lunn R, et al. Prophylaxis of candidiasis in patients with leukemia and bone marrow transplants. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996;81(3):291-6
- Ship JA, Vissink A, Challacombe SJ. Use of prophylactic antifungals in the immunocompromised host. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007;103(Suppl):S6 e1-14
- Ueta E, Tanida T, Yoneda K, et al. Increase of Candida cell virulence by anticancer drugs and irradiation. Oral Microbiol Immunol 2001;16(4):243-9
- Li L, Redding S, Dongari-Bagtzoglou A. Candida glabrata: an emerging oral opportunistic pathogen. J Dent Res 2007;86(3):204-15
- de Pauw BE, Rubin RH. Empiric versus preemptive therapy in the management of febrile neutropenia in the patient being treated for hematologic malignancy. Transpl Infect Dis 2006;8(1):1-2
- Guidelines for the treatment of candidiasis. Available from: http://www.idsociety.org/content.aspx?id=9200#cand [Cited 2008]
- Pienaar ED, Young T, Holmes H. Interventions for the prevention and management of oropharyngeal candidiasis associated with HIV infection in adults and children. Cochrane Database Syst Rev 2006;3:CD003940
- Vasquez EM, Shin GP, Sifontis N, Benedetti E. Concomitant clotrimazole therapy more than doubles the relative oral bioavailability of tacrolimus. Ther Drug Monit 2005;27(5):587-91
- Vasquez E, Pollak R, Benedetti E. Clotrimazole increases tacrolimus blood levels: a drug interaction in kidney transplant patients. Clin Transplant 2001;15(2):95-9
- Kuriyama T, Williams DW, Bagg J, et al. In vitro susceptibility of oral Candida to seven antifungal agents. Oral Microbiol Immunol 2005;20(6):349-53
- U.S. National Library of Medicine, 2008
- Dictionary.com. 2008. Available from: http://dictionary.reference.com/browse/gentian%20violet [Cited 8 November 2008]
- Su CW, Gaskie S, Jamieson B, Triezenberg D. Clinical inquiries. What is the best treatment for oral thrush in healthy infants? J Fam Pract 2008;57(7):484-5
- Quatresooz P, Vroome V, Borgers M, et al. Novelties in the multifaceted miconazole effects on skin disorders. Expert Opin Pharmacother 2008;9(11):1927-34
- Barasch A, Griffin AV. Miconazole revisited: new evidence of antifungal efficacy from laboratory and clinical trials. Future Microbiol 2008;3:265-9
- Fothergill AW. Miconazole: a historical perspective. Expert Rev Anti Infect Ther 2006;4(2):171-5
- Bensadoun RJ, Daoud J, El Gueddari B, et al. Comparison of the efficacy and safety of miconazole 50-mg mucoadhesive buccal tablets with miconazole 500-mg gel in the treatment of oropharyngeal candidiasis: a prospective, randomized, single-blind, multicenter, comparative, phase III trial in patients treated with radiotherapy for head and neck cancer. Cancer 2008;112(1):204-11
- Bastian HL, Rindum J, Lindeberg H. A double-dummy, double-blind, placebo-controlled phase III study comparing the efficacy and efficiency of miconazole chewing gum with a known drug (Brentan gel) and a placebo in patients with oral candidosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004;98(4):423-8
- Van Roey J, Haxaire M, Kamya M, et al. Comparative efficacy of topical therapy with a slow-release mucoadhesive buccal tablet containing miconazole nitrate versus systemic therapy with ketoconazole in HIV-positive patients with oropharyngeal candidiasis. J Acquir Immune Defic Syndr 2004;35(2):144-50
- Cha R, Sobel JD. Fluconazole for the treatment of candidiasis: 15 years experience. Expert Rev Anti Infect Ther 2004;2(3):357-66
- Martins MD, Rex JH. Fluconazole suspension for oropharyngeal candidiasis unresponsive to tablets. Ann Intern Med 1997;126(4):332-3
- Hamza OJ, Matee MI, Bruggemann RJ, et al. Single-dose fluconazole versus standard 2-week therapy for oropharyngeal candidiasis in HIV-infected patients: a randomized, double-blind, double-dummy trial. Clin Infect Dis 2008;47(10):1270-6
- Enoch DA, Ludlam HA, Brown NM. Invasive fungal infections: a review of epidemiology and management options. J Med Microbiol 2006;55(Pt 7):809-18
- LEXI-COMP Online for Dentistry. Available from: www.crlonline.com [Cited 2008 November 2008]
- Petrikkos G, Skiada A. Recent advances in antifungal chemotherapy. Int J Antimicrob Agents 2007;30(2):108-17
- Vazquez JA, Skiest DJ, Nieto L, et al. A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin Infect Dis 2006;42(8):1179-86
- Skiest DJ, Vazquez JA, Anstead GM, et al. Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. Clin Infect Dis 2007;44(4):607-14
- Corporation S-P. Schering-Plough Announces FDA Approval of NOXAFIL(R) (Posaconazole) for Treatment of Oropharyngeal Candidiasis (OPC) 2006 22 September 2008. Available from: http://www.schering-plough.com/schering_plough/news/release.jsp?releaseID=919520 [Cited News Release]
- Rachwalski EJ, Wieczorkiewicz JT, Scheetz MH. Posaconazole: an oral triazole with an extended spectrum of activity. Ann Pharmacother 2008;42(10):1429-38
- Rautemaa R, Richardson M, Pfaller MA, et al. Activity of amphotericin B, anidulafungin, caspofungin, micafungin, posaconazole, and voriconazole against Candida albicans with decreased susceptibility to fluconazole from APECED patients on long-term azole treatment of chronic mucocutaneous candidiasis. Diagn Microbiol Infect Dis 2008;62(2):182-5
- Shahum A, Liskova A, Kalavsky E, Krcmery V. Voriconazole resistant Candida spp. and Saccharomyces spp. isolates from oropharyngeal candidiasis from Cambodian children with AIDS not pretreated with azoles (letter). Scand J Infect Dis 2007;39(3):286-7
- Trifilio S, Pennick G, Pi J, et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer 2007;109(8):1532-5
- Maschmeyer G, Haas A. Voriconazole: a broad spectrum triazole for the treatment of serious and invasive fungal infections. Future Microbiol 2006;1:365-85
- Joseph JM, Kim R, Reboli AC. Anidulafungin: a drug evaluation of a new echinocandin. Expert Opin Pharmacother 2008;9(13):2339-48
- Patel M, Kunz DF, Trivedi VM, et al. Initial management of candidemia at an academic medical center: evaluation of the IDSA guidelines. Diagn Microbiol Infect Dis 2005;52(1):29-34
- Weig M, Brown AJ. Genomics and the development of new diagnostics and anti-Candida drugs. Trends Microbiol 2007;15(7):310-7